canakinumab
novartis
['nsclc', 'canakinumab', 'canopy-a', 'sclc']
canakinumab in the cantos study was associated with a reduction in nsclc incidence. led to canopy-a: large study of adjuvant canakinumab after surgery and chemotherapy for nsclc. #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him